(RS)-3-(4-ethoxyphenyl)-6,7-difluoro-3-hydroxyindolin-2-one | 1247028-68-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: (RS)-3-(4-ethoxyphenyl)-6,7-difluoro-3-hydroxyindolin-2-one
• 英文别名: 3-(4-ethoxyphenyl)-6,7-difluoro-3-hydroxy-1H-indol-2-one
• CAS: 1247028-68-7
• 化学式: C₁₆H₁₃F₂NO₃
• 分子量: 305.281
• InChiKey: OOELMDWYZDJCIJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  58.6
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (RS)-3-(4-ethoxyphenyl)-6,7-difluoro-3-hydroxyindolin-2-one 、 苯酚 在 对甲苯磺酸 作用下， 以 1,2-二氯乙烷 为溶剂， 以85%的产率得到(RS)-3-(4-ethoxyphenyl)-6,7-difluoro-3-(4-hydroxyphenyl)indolin-2-one
  参考文献：
  名称：

  Synthesis and Antitumor Effect in Vitro and in Vivo of Substituted 1,3-Dihydroindole-2-ones

  摘要：

  Optimization of the anticancer activity for a class of compounds built on a 1,3-dihydroindole-2-one scaffold was performed. In comparison with recently published derivatives of oxyphenisatin the new analogues exhibited an equally potent antiproliferative activity in vitro and improved tolerability and activity in vivo. The best compounds from this series showed low nanomolar antiproliferative activity toward a series of cancer cell lines (compound (S)-38: IC(50) of 0.48 and 2 nM in MCF-7 (breast) and PC3 (prostate), respectively) and potent antitumor effects in well tolerated doses in xenograft models. The racemic compound (R.S)-38 showed complete tumor regression at a dose of 20 mg/kg administered iv on days 1 and 7 in a PC3 rat xenograft.

  DOI：

  10.1021/jm100763j
• 作为产物：
  描述：

  6,7-二氟-1H-吲哚-2,3-二酮 、 magnesium,ethoxybenzene,bromide 以 四氢呋喃 为溶剂， 反应 0.5h， 以62%的产率得到(RS)-3-(4-ethoxyphenyl)-6,7-difluoro-3-hydroxyindolin-2-one
  参考文献：
  名称：

  Synthesis and Antitumor Effect in Vitro and in Vivo of Substituted 1,3-Dihydroindole-2-ones

  摘要：

  Optimization of the anticancer activity for a class of compounds built on a 1,3-dihydroindole-2-one scaffold was performed. In comparison with recently published derivatives of oxyphenisatin the new analogues exhibited an equally potent antiproliferative activity in vitro and improved tolerability and activity in vivo. The best compounds from this series showed low nanomolar antiproliferative activity toward a series of cancer cell lines (compound (S)-38: IC(50) of 0.48 and 2 nM in MCF-7 (breast) and PC3 (prostate), respectively) and potent antitumor effects in well tolerated doses in xenograft models. The racemic compound (R.S)-38 showed complete tumor regression at a dose of 20 mg/kg administered iv on days 1 and 7 in a PC3 rat xenograft.

  DOI：

  10.1021/jm100763j

文献信息

• Synthesis and Antitumor Effect in Vitro and in Vivo of Substituted 1,3-Dihydroindole-2-ones
  作者：Mette K. Christensen、Kamille D. Erichsen、Christina Trojel-Hansen、Jette Tjørnelund、Søren J. Nielsen、Karla Frydenvang、Tommy N. Johansen、Birgitte Nielsen、Maxwell Sehested、Peter B. Jensen、Martins Ikaunieks、Andrei Zaichenko、Einars Loza、Ivars Kalvinsh、Fredrik Björkling

  DOI：10.1021/jm100763j

  日期：2010.10.14

  Optimization of the anticancer activity for a class of compounds built on a 1,3-dihydroindole-2-one scaffold was performed. In comparison with recently published derivatives of oxyphenisatin the new analogues exhibited an equally potent antiproliferative activity in vitro and improved tolerability and activity in vivo. The best compounds from this series showed low nanomolar antiproliferative activity toward a series of cancer cell lines (compound (S)-38: IC(50) of 0.48 and 2 nM in MCF-7 (breast) and PC3 (prostate), respectively) and potent antitumor effects in well tolerated doses in xenograft models. The racemic compound (R.S)-38 showed complete tumor regression at a dose of 20 mg/kg administered iv on days 1 and 7 in a PC3 rat xenograft.